Fredrick B. Hagemeister, Jr, MD, on Using Rituximab Maintenance
2016 Pan Pacific Lymphoma ConferenceFredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.
Related Videos
Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update
Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of n...
Bruce D. Cheson, MD, and Julie M. Vose, MD, MBA, on Staging Lymphoma
Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be s...
David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells
David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.
Susan M. O’Brien, MD, on ALL/Lymphoma: Upfront and Salvage Treatments in Older Patients
Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive res...
Julie M. Vose, MD, MBA, on Highlights of Pan Pacific Lymphoma 2016
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.
